Polyiclc

Oligodendroglioma

Nicholas ButowskiPhase 1Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 89/ 100

Competitive context

8 Active assets in the Oligodendroglioma cohort.

Asset / Sponsor	Phase	Rating
Nivolumab University of Florida	Phase 2	B
Safusidenib Nuvation Bio Inc.	Phase 3	B
(+)-VINCRISTINE National Cancer Institute (NCI)	Phase 2	B
Irinotecan National Cancer Institute (NCI)	Phase 2	B
Trebananib National Cancer Institute (NCI)	Phase 2	B

View all 25 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant

B

Indicative ·

63 / 100

melanomaDormant

B

Indicative ·

63 / 100

ocular melanomaDormant

B

Indicative ·

63 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.